I agree with your all your comments. The recognition by Governments around the world of the cost they have to bear to support overweight people will ensure that they financially contribute to any medical forays into drug development that reduces weight issues.
The potential share that RMD may obtain of the currently large, untouched portion of the total addressable sleep apnea market may smooth out any sales regression in the short-term but scientific development is an issue that needs to be watched closely as a long-term holder of this stock.
I agree with your all your comments. The recognition by...
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.96 |
Change
0.210(0.66%) |
Mkt cap ! $20.29B | |||
| Open | High | Low | Value | Volume |
| $31.93 | $32.00 | $31.81 | $49.00M | 1.534M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8794 | $31.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.96 | 565 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RMD (ASX) Chart |